Class-Action Securities Suits On The Rise Against Life-Science Firms, Especially Smaller Ones
Executive Summary
A recent report from law firm Dechert LLP shows that the number of class-action cases brought against life-sciences companies has spiked in recent years, up from 27 in 2012 to 88 in 2017. The trend is most pronounced against smaller-cap companies, an attorney behind the report explains.
You may also be interested in...
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Implant
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
News We’re Watching: Lung Preservation System Goes National, De Novo For MMI, Brazil’s ANVISA To Recognize Overseas Approvals
This week, Paragonix announced that its BAROguard lung preservation system is now available throughout the US; Brazil planned to leverage some foreign device approvals; Medical Microinstruments’ Symani Surgical System won de novo clearance; and the FDA updated its safety warnings for Essure and certain plastic syringes.
FDA Asked To Withdraw Approval Of Test Evaluating Opioid Addiction Risk
Dozens of researchers signed a letter condemning the AvertD test from SOLVD, which looks for genes that may contribute to a propensity toward opioid addiction. But the FDA and the manufacturer both say the test is effective.